Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics is a commercial-stage medical diagnostics technology company that is currently in its early stage of commercialization. It is focused on patients with gastroesophageal reflux disease (GERD), which puts them at risk for developing esophageal precancer and cancer. The company's two main products, EsoCheck and EsoGuard, have been supported by leading gastroenterology specialty associations and are seen as an acceptable alternative to endoscopy. Lucid plans to ramp up commercialization and gain approval for Medicare coverage, which we believe will be catalysts for the stock. The company reported Q1 results slightly lower than expected, but we believe revenue will significantly increase in 2026/27. With an attractive current valuation and multiple growth levers ahead, we are optimistic about the company's potential success, although there are risks involved such as uncertainties with reimbursement and commercial execution. There is also potential competition in the market, but parallels can be drawn between Lucid's EsoGuard test and Exact Sciences' Cologuard test, which has seen significant success.

Bears say

Lucid Diagnostics is a commercial-stage medical diagnostics technology company that focuses on patients with reflux disease who are at risk of developing esophageal precancer and cancer. While the company has received support from medical associations and is expected to receive Medicare coverage, there are risks to achieving projected sales, including regulatory approvals, competition, and changes in healthcare priorities. Additionally, the company may need to increase its sales force to meet its targets and has yet to achieve significant payor coverage, which could limit its potential for growth. Ultimately, there are several potential barriers that could impact the company's financial success.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Aug 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.